IQ / USDT

ARK / USDT

ARK / TRY

BIGTIME / USDT

BIGTIME / USDC

BIO / BNB

ACA / BTC

BIO / USDT

BIO / TRY

BIO / USDC

STRAX / USDT

ARDR / BTC

ARDR / USDT

GAS / BTC

GAS / TRY

BABY / FDUSD

GAS / USDT

BABY / BNB

BABY / TRY

BABY / USDC

FUSION FINANCE LIMITED

SECMARK CONSULTANCY LTD

GOLDSTAR POWER LIMITED

OSWAL GREENTECH LIMITED

SMS LIFESCIENCES (I) LTD

OSWAL AGRO MILLS LTD

FACT LTD

DEEM ROLL TECH LIMITED

ASHIMA LTD

AGARWAL TOUGH GLASS IND L

AKME FINTRADE (INDIA) LTD

BODHI TREE MULTIMEDIA LTD

VIKAS LIFECARE LIMITED

CROP LIFE SCIENCE LIMITED

RAJ OIL MILLS LIMITED

TWAMEV CONS AND INFRA LTD

SAROJA PHARMA INDUS IND L

ARISTO BIO T AND LIFESC L

ACCENT MICROCELL LIMITED

DYNEMIC PRODUCTS LIMITED

Click here to get full coverage on Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC - Targeted Oncology

Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC  Targeted Oncology

Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC - Targeted Oncology

Click here to get full coverage on Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis | Blood Cancer Journal - Nature

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis | Blood Cancer Journal  Nature

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis | Blood Cancer Journal - Nature

Click here to get full coverage on A Case of HIV With PCNSL Refractory to MTX-Based Therapy and Immunotherapy - Hematology Advisor

A Case of HIV With PCNSL Refractory to MTX-Based Therapy and Immunotherapy  Hematology Advisor

A Case of HIV With PCNSL Refractory to MTX-Based Therapy and Immunotherapy - Hematology Advisor

Click here to get full coverage on Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer - Targeted Oncology

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer  Targeted Oncology

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer - Targeted Oncology

Click here to get full coverage on Poor Outcomes Persist in Patients With Rel/Ref Multiple Myeloma - Oncology Nurse Advisor

Poor Outcomes Persist in Patients With Rel/Ref Multiple Myeloma  Oncology Nurse Advisor

Poor Outcomes Persist in Patients With Rel/Ref Multiple Myeloma - Oncology Nurse Advisor

Click here to get full coverage on Wear-Resistant And Refractory Plastics Market Size by Type, Application, and Regional Outlook - openPR.com

Wear-Resistant And Refractory Plastics Market Size by Type, Application, and Regional Outlook  openPR.com

Wear-Resistant And Refractory Plastics Market Size by Type, Application, and Regional Outlook - openPR.com

Click here to get full coverage on Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma - The New England Journal of Medicine

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma  The New England Journal of Medicine

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma - The New England Journal of Medicine

Click here to get full coverage on AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML - OncLive

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML  OncLive

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML - OncLive

Click here to get full coverage on Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study - ASCO Publications

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study  ASCO Publications

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study - ASCO Publications

Click here to get full coverage on Refractory Angina - www.heart.org

Refractory Angina - www.heart.org

Click here to get full coverage on Evaluation and management of pediatric refractory constipation: Recommendations from the NASPGHAN neurogastroenterology and motility committee - Wiley Online Library

Evaluation and management of pediatric refractory constipation: Recommendations from the NASPGHAN neurogastroenterology and motility committee  Wiley Online Library

Evaluation and management of pediatric refractory constipation: Recommendations from the NASPGHAN neurogastroenterology and motility committee - Wiley Online Library

Click here to get full coverage on Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax | Leukemia - Nature

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax | Leukemia  Nature

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax | Leukemia - Nature

Click here to get full coverage on Liso-Cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma - OncLive

Liso-Cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma  OncLive

Liso-Cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma - OncLive

Click here to get full coverage on Geopolymer Market Trends, Innovations & Opportunities By 2032| - openPR.com

Geopolymer Market Trends, Innovations & Opportunities By 2032|  openPR.com

Geopolymer Market Trends, Innovations & Opportunities By 2032| - openPR.com

Click here to get full coverage on Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma - Nature

Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma  Nature

Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma - Nature

Click here to get full coverage on Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape - Targeted Oncology

Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape  Targeted Oncology

Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape - Targeted Oncology

Click here to get full coverage on Oncolytic virus VG161 in refractory hepatocellular carcinoma - Nature

Oncolytic virus VG161 in refractory hepatocellular carcinoma  Nature

Oncolytic virus VG161 in refractory hepatocellular carcinoma - Nature

Click here to get full coverage on Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis - Nature

Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis  Nature

Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis - Nature

Click here to get full coverage on Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma - Nature

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma  Nature

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma - Nature

Click here to get full coverage on Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial - Nature

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial  Nature

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial - Nature

Click here to get full coverage on Designing ductile refractory high-entropy alloys - Nature

Designing ductile refractory high-entropy alloys  Nature

Designing ductile refractory high-entropy alloys - Nature

Click here to get full coverage on Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial - Nature

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial  Nature

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial - Nature

Click here to get full coverage on ‘My cough interferes with everything’: New research could help refractory chronic cough patients after decades of depression, pain, and sleep loss - GSK

‘My cough interferes with everything’: New research could help refractory chronic cough patients after decades of depression, pain, and sleep loss  GSK

‘My cough interferes with everything’: New research could help refractory chronic cough patients after decades of depression, pain, and sleep loss - GSK

Click here to get full coverage on The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development - Nature

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development  Nature

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development - Nature

Click here to get full coverage on The efficacy of penoscrotal decompression for refractory ischaemic priapism: a systematic review and meta-analysis - Nature

The efficacy of penoscrotal decompression for refractory ischaemic priapism: a systematic review and meta-analysis  Nature

The efficacy of penoscrotal decompression for refractory ischaemic priapism: a systematic review and meta-analysis - Nature

Click here to get full coverage on Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease - The New England Journal of Medicine

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease  The New England Journal of Medicine

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease - The New England Journal of Medicine

Click here to get full coverage on LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis) | Leukemia - Nature

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis) | Leukemia  Nature

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis) | Leukemia - Nature

Click here to get full coverage on Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome - OncLive

Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome  OncLive

Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome - OncLive

Click here to get full coverage on Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study - Wiley Online Library

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study  Wiley Online Library

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study - Wiley Online Library

Click here to get full coverage on Data-driven design of novel lightweight refractory high-entropy alloys with superb hardness and corrosion resistance - Nature

Data-driven design of novel lightweight refractory high-entropy alloys with superb hardness and corrosion resistance  Nature

Data-driven design of novel lightweight refractory high-entropy alloys with superb hardness and corrosion resistance - Nature

Click here to get full coverage on Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 - Nature

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3  Nature

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 - Nature

Click here to get full coverage on Abstract 4146931: The effectiveness of coronary sinus reducer in refractory angina: A meta-analysis of 18 studies - American Heart Association Journals

Abstract 4146931: The effectiveness of coronary sinus reducer in refractory angina: A meta-analysis of 18 studies  American Heart Association Journals

Abstract 4146931: The effectiveness of coronary sinus reducer in refractory angina: A meta-analysis of 18 studies - American Heart Association Journals

Click here to get full coverage on FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL - OncLive

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL  OncLive

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL - OncLive

Click here to get full coverage on FDA Approves New Combined Therapy for Relapsed or Refractory DLBCL - Oncology Nurse Advisor

FDA Approves New Combined Therapy for Relapsed or Refractory DLBCL  Oncology Nurse Advisor

FDA Approves New Combined Therapy for Relapsed or Refractory DLBCL - Oncology Nurse Advisor

Click here to get full coverage on Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies - The Lancet

Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies  The Lancet

Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies - The Lancet

Click here to get full coverage on FDA to Review sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL - OncLive

FDA to Review sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL  OncLive

FDA to Review sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL - OncLive

Click here to get full coverage on Innovations and Growth in the Refractory Cement Market: - GlobeNewswire

Innovations and Growth in the Refractory Cement Market:  GlobeNewswire

Innovations and Growth in the Refractory Cement Market: - GlobeNewswire

Click here to get full coverage on Nilachal Refractories Faces Trading Volatility Amidst Declining Financial Performance - MarketsMojo

Nilachal Refractories Faces Trading Volatility Amidst Declining Financial Performance  MarketsMojo

Nilachal Refractories Faces Trading Volatility Amidst Declining Financial Performance - MarketsMojo

Click here to get full coverage on Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma - Nature

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma  Nature

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma - Nature

Click here to get full coverage on Chemotherapeutic hormesis induced by the tumor microenvironment in refractory ovarian cancer - Nature

Chemotherapeutic hormesis induced by the tumor microenvironment in refractory ovarian cancer  Nature

Chemotherapeutic hormesis induced by the tumor microenvironment in refractory ovarian cancer - Nature

Click here to get full coverage on The world's first CCU plant in the refractory industry - RHI Magnesita

The world's first CCU plant in the refractory industry  RHI Magnesita

The world's first CCU plant in the refractory industry - RHI Magnesita

Click here to get full coverage on Enhancing Refractory Recycling: The Role of Automated Sensor-Based Sorting Systems - RHI Magnesita

Enhancing Refractory Recycling: The Role of Automated Sensor-Based Sorting Systems  RHI Magnesita

Enhancing Refractory Recycling: The Role of Automated Sensor-Based Sorting Systems - RHI Magnesita

Click here to get full coverage on Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group  The Lancet

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet

Click here to get full coverage on The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy - Frontiers

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy  Frontiers

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy - Frontiers

Click here to get full coverage on Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma - OncLive

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma  OncLive

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma - OncLive

Click here to get full coverage on Unraveling dislocation-based strengthening in refractory multi-principal element alloys - Nature

Unraveling dislocation-based strengthening in refractory multi-principal element alloys  Nature

Unraveling dislocation-based strengthening in refractory multi-principal element alloys - Nature

Click here to get full coverage on Abstract 4144819: Efficacy and Safety of Coronary Sinus Reducer for Refractory Angina: A Systematic Review and Meta-analysis of Randomized Controlled Trials - American Heart Association Journals

Abstract 4144819: Efficacy and Safety of Coronary Sinus Reducer for Refractory Angina: A Systematic Review and Meta-analysis of Randomized Controlled Trials  American Heart Association Journals

Abstract 4144819: Efficacy and Safety of Coronary Sinus Reducer for Refractory Angina: A Systematic Review and Meta-analysis of Randomized Controlled Trials - American Heart Association Journals

Click here to get full coverage on Bayesian blacksmithing: discovering thermomechanical properties and deformation mechanisms in high-entropy refractory alloys - Nature

Bayesian blacksmithing: discovering thermomechanical properties and deformation mechanisms in high-entropy refractory alloys  Nature

Bayesian blacksmithing: discovering thermomechanical properties and deformation mechanisms in high-entropy refractory alloys - Nature

Click here to get full coverage on Use of Biologic Agents to Treat Refractory Hidradenitis Suppurativa: a Primary Care Case Study - Clinical Advisor

Use of Biologic Agents to Treat Refractory Hidradenitis Suppurativa: a Primary Care Case Study  Clinical Advisor

Use of Biologic Agents to Treat Refractory Hidradenitis Suppurativa: a Primary Care Case Study - Clinical Advisor

Click here to get full coverage on Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study - The Lancet

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study  The Lancet

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study - The Lancet

Click here to get full coverage on Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study - The Lancet

Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study  The Lancet

Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study - The Lancet

Click here to get full coverage on Energy-efficient treatment of refractory industrial effluent using flow-through electrochemical processes: Oxidation mechanisms and reduction of chlorinated byproducts - ScienceDirect.com

Energy-efficient treatment of refractory industrial effluent using flow-through electrochemical processes: Oxidation mechanisms and reduction of chlorinated byproducts  ScienceDirect.com

Energy-efficient treatment of refractory industrial effluent using flow-through electrochemical processes: Oxidation mechanisms and reduction of chlorinated byproducts - ScienceDirect.com

Click here to get full coverage on Refractory Material Market Size Expected to Reach USD 43.97 Billion by 2033 - GlobeNewswire

Refractory Material Market Size Expected to Reach USD 43.97 Billion by 2033  GlobeNewswire

Refractory Material Market Size Expected to Reach USD 43.97 Billion by 2033 - GlobeNewswire

Click here to get full coverage on Response to PARP Inhibition in BARD1 -Mutated Refractory Neuroblastoma - The New England Journal of Medicine

Response to PARP Inhibition in BARD1 -Mutated Refractory Neuroblastoma  The New England Journal of Medicine

REFRACTORY

Price Chart

Key Statistics

Technicals

About REFRACTORY

Latest News

Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC - Targeted Oncology

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis | Blood Cancer Journal - Nature

A Case of HIV With PCNSL Refractory to MTX-Based Therapy and Immunotherapy - Hematology Advisor

Advanced Charts

Top Gainers

Top Losers